Safety, Immunogenicity, and Antibody Persistence of a New Meningococcal Group A Conjugate Vaccine in Healthy Indian Adults

This article, published in the journal Vaccine, discusses a double-blind, randomized, controlled Phase 1 study in India to assess safety, immunogenicity, and antibody persistence of the new meningococcal group A conjugate vaccine (PsA-TT) in healthy volunteers aged 18 to 35 years. The study found that the new PsA-TT vaccine was shown to be safe, immunogenic, and able to elicit persistent functional antibody titers in adults, which opens the prospective for further development and licensure of the vaccine to eliminate epidemic meningitis in sub-Saharan Africa. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author(s): Kshirsagar N, Mur N, Thatte U, et al.

Published: 2007

  • Visit web page (English)

    (Located at www.ncbi.nlm.nih.gov)

    Citation: Kshirsagar N, Mur N, Thatte U, et al. Safety, Immunogenicity, and Antibody Persistence of a New Meningococcal Group A Conjugate Vaccine in Healthy Indian Adults. Vaccine. 2007;25(Suppl. 1):A101-A107.